RNS announcements

Click on an announcement to view (opens in new window) or conduct a search.

Read the latest news updates for 4D pharma plc.

Click on a news or publication title to read full details.

4D pharma will present at the 2nd Annual Microbiome Discovery & Development Congress which takes place June 7 - 8 in Berlin. The company will provide an update on MRx0518, the company's lead live biotherapeutic candidate in the field of immuno-oncology, which is set to hit the clinic later this year across multiple therapeutic settings.

The presentation will be:

Live Biotherapeutics – From Concept To Clinic In Immuno-Oncology, presented by Imke Mulder, Research Director

Download the presentation here.

4D pharma will present clinical data on its IBS programme at the Digestive Disease Week 2018 Meeting from June 2 - 5 in Washington D.C. The company will present a poster on its lead candidate, Blautix, a single-strain live biotherapeutic in development for the treatment of IBS-C and IBS-D. The poster presentation will feature clinical data from a Phase Ib study of Blautix in IBS patients and healthy individuals.

The data presented are:

Phase I Randomised Controlled Study of a Single-Strain Live Biotherapeutic (Blautia hydrogenotrophica) in the treatment of patients with Irritable Bowel Syndrome (IBS): Effects on the Microbiome, presented by John Weinberg, MD, Chief Medical Officer.

Download here:

4D pharma will participate in the Global Engage Microbiome Futures Conference in New York on May 23rd.

Company CEO, Duncan Peyton, will join other microbiome Key Opinion Leaders in a panel discussion on the future of microbiome research and commercialisation.

For further information, please see the Microbiome Futures website (http://www.global-engage.com/event/microbiome-futures/)

4D pharma will present data outlining key aspects of the mode of action of MRx0518 – the company’s single-strain live biotherapeutic in immuno-oncology – at the Microbiome R&D Business Collaboration Forum: Europe meeting on March 21 in Rotterdam.

Research carried out by 4D has identified a specific component of the bacteria, flaA, that plays a key role in the activity of MRx0518 by stimulating pathways that are known to be associated with the body's response to cancer. Interaction of flaA with the human protein Toll Like Receptor 5 (TLR5) has been linked to the activity of MRx0518 in pre-clinical cancer models and this will be investigated further in upcoming clinical trials.

Download PDF

4D pharma will present preclinical data on its immuno-oncology programme at the Cell-Weizmann Institute of Science Symposium: Next Gen Immunology meeting from February 11 - 14 in Rehovot, Israel. The company will present a poster on its lead candidate, MRx0518, a single-strain live biotherapeutic under investigation for the treatment of a range of solid tumour types, which is set to hit the clinic in 2018.

The data presented are:

Live biotherapeutics and immuno-oncology: from discovery to efficacy studies, presented by Anna Etorre, PhD, 4D Pharma Research.

Download PDF (920 KB)

4D pharma will present preclinical data on its asthma programme at the Keystone Symposium: Microbiome in Health and Disease meeting from February 5 - 9 in Keystone, Colorado. The company will present a poster on its lead candidate, MRx0004, a single-strain live biotherapeutic under investigation for the treatment of asthma which is set to hit the clinic in 2018.

The data presented are:

Immunomodulatory effects of a commensal gut microbe alleviate inflammatory responses in an animal model of severe asthma through reduction of neutrophil infiltration in the lung, presented by Phillip Cowie, PhD, 4D Pharma Research.

Download PDF

4D pharma will present preclinical data on its rheumatoid arthritis programme at the Keystone Symposium: Microbiome in Health and Disease meeting from February 5 - 9 in Keystone, Colorado. The company will present a poster on its lead candidate, MRx0006, a single-strain live biotherapeutic under investigation for the treatment of rheumatoid arthritis.

The data presented are:

Immunomodulatory effects of a commensal gut microbe alleviate inflammatory responses in an animal model of severe asthma through reduction of neutrophil infiltration in the lung, presented by Emma Raftis, PhD, 4D Pharma Research.

Download PDF

BACK TO TOP